Statement on the erratum by DSM
- Industry
- Internal
- Scientific
We would like to address the recent false statement by DSM regarding the simultaneous use of HyD® and Panbonis® in diets for poultry, swine and ruminants.
Apparently, the European Commission (EC) approval of HyD® (EU 2024/1070) in April 2024, has led to misinterpretation by DSM, which resulted in wrong statements in the market. When addressing this to the DSM legal department, they corrected this statement on 5th September 2024 on the DSM website as an erratum statement, clearly stating there is no legal limitation for the application of Panbonis® in combination with Hy-D® in poultry, swine and ruminants.”
For reference, see: www.dsm.com/anh/news/press-releases/2024/2024-07-15-hy-d-correction.html
Statement by Herbonis: 19SEP2024_Statement_ERRATUM_DSM.pdf
What was the background for these false statements?
In regulation EU 2024/1070 the following comment was made by the EC: "[…] As 25-hydroxycholecalciferol (25(OH)D3) depresses the activity of 1α-hydroxylase in the kidney, the Commission considers that the simultaneous use of 1,25-dihydroxycholecalciferol from Solanum glaucophyllum extract with that additive should not be allowed. […]".
To clarify:
The restriction only pertains to the simultaneous use of 25(OH)D3 with Solanum glaucophyllum extract. Herbonis has applied for a registration an extract of Solanum glaucophyllum as a feed additive and a bolus ingredient for ruminants.
This restriction does not apply to products based on Solanum glaucophyllum standardized leaves (i.e. Panbonis®), which is a feed material and safe to be used in diets for poultry and pigs (EFSA Journal 2015;13(1):3967). The EC also allows waxy-leaf nightshade meal with a defined release pattern to be used as an ingredient for the reduction of the risk of milk fever and subclinical hypocalcemia (EC 2020/354; PARNUT entry nr 60).
Thank you for your continued trust in our products.